TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization
(TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar
carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University